US Patent

US9919024 — Formulations of guanylate cyclase C agonists and methods of use

Method of Use · Assigned to Synergy Pharmaceuticals Inc · Expires 2031-09-15 · 5y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects low-dose formulations of guanylate cyclase-C agonist peptides and methods for their use, either alone or in combination with other therapeutic agents.

USPTO Abstract

The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2230 — Trulance

Patent Metadata

Patent number
US9919024
Jurisdiction
US
Classification
Method of Use
Expires
2031-09-15
Drug substance claim
No
Drug product claim
No
Assignee
Synergy Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.